Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL29840804

CCCCc1nc2c(N)nnc(OC(C)C)c2n1Cc1ccc(CN)cc1.O=C(O)C(F)(F)F

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 20/20 0.53
TLR8 Q9NR97 6/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL29109922 1.00 TLR7 (0.53) TLR7TLR8
Trifluoroacetic Acid SCHEMBL29840885 0.94 TLR7 (0.56) TLR7TLR8
Trifluoroacetic Acid SCHEMBL29109801 0.94 TLR7 (0.56) TLR7TLR8
Trifluoroacetic Acid SCHEMBL29840701 0.92 TLR7 (0.52) TLR7TLR8
Trifluoroacetic Acid SCHEMBL29109862 0.92 TLR7 (0.52) TLR7TLR8
SCHEMBL29109915 0.91 TLR7 (0.59) TLR7TLR8
SCHEMBL29840784 0.91 TLR7 (0.59) TLR7TLR8
SCHEMBL29109854 0.85 TLR7 (0.51) TLR7TLR8
SCHEMBL29840833 0.85 TLR7 (0.51) TLR7TLR8
SCHEMBL29109822 0.85 TLR7 (0.60) TLR7TLR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4288438-A1 DERIVATIVES OF IMIDAZO[4,5-D]PYRIDAZINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION Sanofi (FR) 2023-12-13 EP claimed
WO-2022167438-A1 DERIVATIVES OF IMIDAZO[4,5-d]PYRIDAZINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI (FR) 2022-08-11 WO claimed
US-12583861-B2 Derivatives of imidazo[4,5-d]pyridazine, their preparation and their therapeutic application SANOFI (FR) 2026-03-24 US disclosed
EP-4288438-B1 DERIVATIVES OF IMIDAZO[4,5-D]PYRIDAZINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI SA (FR) 2026-02-18 EP disclosed
WO-2025031923-A1 IMIDAZO[4,5-D]PYRIDAZINE COMPOUNDS AND CONJUGATES THEREOF, THEIR PREPARATION, AND THEIR THERAPEUTIC APPLICATIONS SANOFI (FR) 2025-02-13 WO disclosed
US-20240158401-A1 DERIVATIVES OF IMIDAZO[4,5-d]PYRIDAZINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI (FR) 2024-05-16 US disclosed
EP-4288438-A1 DERIVATIVES OF IMIDAZO[4,5-D]PYRIDAZINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION Sanofi (FR) 2023-12-13 EP disclosed
WO-2022167438-A1 DERIVATIVES OF IMIDAZO[4,5-d]PYRIDAZINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI (FR) 2022-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12583861-B2 Derivatives of imidazo[4,5-d]pyridazine, their preparation and their therapeutic application TLR7, TLR8, TLR6 TLR7 1/4885TLR8 2/4885
US-20240158401-A1 DERIVATIVES OF IMIDAZO[4,5-d]PYRIDAZINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION TLR7, TLR8, TLR6 TLR7 1/4885TLR8 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.